

## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to:


Fritsche A, Wagner R, Heni M et al.

Different effects of lifestyle intervention in high- and low-risk prediabetes -  
Results of the randomized controlled Prediabetes Lifestyle Intervention Study (PLIS)

## Table of Contents

Appendix Figure 1 .....	3
Appendix Figure 2.....	4
Aggregate percentage of completed lifestyle goals during the study.....	4
Appendix Table 1 .....	5
Participation at different academic diabetes centers where the study was performed. ....	5
Appendix Table 2 .....	6
Exclusion criteria.....	6
Appendix Table 3 .....	7
Full-set analysis on all 1105 participants .....	7
Appendix Table 4:.....	8
Comparison of baseline parameters (mean±SD), low-risk group control versus conventional intervention and high risk group conventional versus intensive intervention.....	8
Appendix Table 5 .....	10
Comparison of baseline variables (mean±SD) non-completers versus completers. ....	10
Appendix Table 6 .....	12
Effect of conventional LI in low risk individuals versus high risk individuals. ....	12
Calculations.....	13
Participating Investigators.....	13
Data and Resource Availability.....	14
Financial information .....	14

Appendix Figure 1




### Change in insulin secretion and sensitivity during the study in the different study arms.

Insulinogenic index (arbitrary units) as marker for insulin secretion is shown as hyperbolic function of insulin sensitivity (insulin sensitivity index, arbitrary units, unadjusted values). Subjects with normal glucose tolerance (NGT, age 18-50 years) from the German TUEF study (1) were used to compute the hyperbolic function (n=1421). The arrows represent baseline values (origin) and values after 12 months of intervention (end) in the study arms.

95 % CI are shown, blue: LR-CTRL, grey: LR-CONV, black: HR-CONV, red: HR-INT.

1. Wagner R, Tabák ÁG, Fehlert E, Fritsche L, Jaghutriz BA, Bánhegyi RJ, Schmid SM, Staiger H, Machicao F, Peter A, Häring HU, Fritsche A, Heni M. Excessive fuel availability amplifies the FTO-mediated obesity risk: results from the TUEF and Whitehall II studies. *Sci Rep* 2017;7:15486

Appendix Figure 2



### Aggregate percentage of completed lifestyle goals during the study.

To scale the aggregate percentage of all lifestyle goals to a maximum of 100%, the number of completed individual goals are downscaled by a factor of 5 (number of individual goals). The aggregate percentage of all completed lifestyle goals was higher in the LR-CONV compared to the HR-CONV ( $p=0.03$ , Wilcoxon-test) and not different between HR-CONV and HR-INT ( $p=0.5$ ).

**Appendix Table 1****Participation at different academic diabetes centers where the study was performed.**

From each study center, about 2 fold of actually included individuals with prediabetes were potentially eligible for the study. For all study centers, a total of n=2561 were potentially eligible.

	Number of participants receiving allocated intervention	Number of participants completing follow up
University Hospital of Tübingen	351	304
University Hospital of Dresden	213	178
German Institute of Human Nutrition, Potsdam	175	137
University Hospital of Heidelberg	104	80
University of Düsseldorf	59	48
Technical University of Munich	106	82
Ludwig Maximilian University Munich	49	40
University Hospital of Leipzig	48	39

**Appendix Table 2**

Exclusion criteria.

<b>Criterion</b>	<b>Specific definition</b>
Pregnancy	
Lactation	
Symptomatic coronary artery disease	
Active malignant disease	Active malignant disease and/or unintended weight loss > 10% over the last 6 months
Elevated liver transaminases	3 times above the upper limit of normal level
Chronic kidney disease	estimated glomerular filtration ratio < 50 ml/min/1.73m <sup>2</sup>
Systemic infection	
Glucocorticoid use	
Severe mental illness	

**Appendix Table 3****Full-set analysis on all 1105 participants**

using multivariable imputation performed on a wide-dataset encompassing basic variables (sex, age, BMI, waist circumference, education, study center), and glycemic variables (glucose during OGTT, AUC glucose, HbA1c), variables on insulin secretion and sensitivity (ISI and IGI), disposition index as well as liver fat content at the visits at 6 months and 12 months. Missing data were imputed for all visits. The imputation was performed using the MICE package in R using default settings (predictive mean matching as default algorithm, 5 iterations) and passive imputation for derived variables (disposition indexes).

	Imputed variables (baseline/follow up)	LOW RISK			HIGH RISK		
		LR-CTRL	LR-CONV	p-value	HR-CONV	HR-INT	p-value
body mass index (kg m <sup>-2</sup> )	0/157	0 [-0.2;0.2]	-0.6 [-0.9;-0.4]	<0.0001	-1.1 [-1.3;-1]	-1.6 [-1.8;-1.4]	<0.0001
fasting glucose (mmol l <sup>-1</sup> )	1/159	-0.13 [-0.21;-0.05]	-0.29 [-0.37;-0.21]	0.004	-0.2 [-0.25;-0.15]	-0.29 [-0.34;-0.24]	0.02
post-challenge glucose (mmol l <sup>-1</sup> )	2/164	-0.49 [-0.76;-0.21]	-0.45 [-0.73;-0.18]	0.9	-0.65 [-0.82;-0.48]	-0.94 [-1.11;-0.77]	0.02
glucose AUC (mmol min l <sup>-1</sup> )	1/163	-8 [-32;17]	-14 [-38;11]	0.7	-76 [-92;-61]	-105 [-120;-89]	0.01
glycated hemoglobin (%)	1/161	0 [0;0]	0 [-0.1;0]	0.2	-0.1 [-0.1;-0.1]	-0.1 [-0.2;-0.1]	0.02
Insulin sensitivity index (AU)	25/181	-1.2 [-1.8;-0.6]	-0.2 [-0.9;0.4]	0.04	1.2 [0.9;1.5]	1.9 [1.6;2.2]	0.004
Insulin secretion (Disposition ind) (AU)	26/184	-236 [-434;-37]	-247 [-446;-48]	0.9	127 [51;203]	168 [92;244]	0.5
Liver fat content (%)	184/437	0.1 [-0.3;0.5]	-0.1 [-0.5;0.3]	0.4	-3.1 [-3.5;-2.6]	-4.5 [-4.9;-4]	<0.0001

**Appendix Table 4:**

Comparison of baseline parameters (mean±SD), low-risk group control versus conventional intervention and high risk group conventional versus intensive intervention.

	<b>LR-CTRL</b>	<b>LR-CONV</b>	<b>HR-CONV</b>	<b>HR-INT</b>
sex female/male (%)	63/38 (62/38)	61/39 (61/39)	186/165 (53/47)	209/147 59/41)
age (years)	57±12	58±11	59±10	59±10
weight (kg)	80.1±16.1	81.3±16.3	92±19.7	92.4±19.2
body mass index (kg m <sup>-2</sup> )	27.9±5.1	28.3±5.3	31.5±5.9	31.9±5.7
waist circumference (cm)	93±12	94±13	105±14	105±14
waist-to-hip ratio	0.89±0.09	0.89±0.08	0.94±0.09	0.94±0.08
systolic blood pressure (mmHg)	135±16	135±17	140±16	139±17
diastolic blood pressure (mmHg)	84±10	85±12	86±10	86±11
fasting glucose (mmol l <sup>-1</sup> )	5.7±0.5	5.7±0.4	5.9±0.5	6.0±0.5
post-challenge glucose (mmol l <sup>-1</sup> )	6.9±1.4	6.7±1.5	7.8±1.7	7.8±1.7
glucose AUC (mmol min l <sup>-1</sup> )	935±112	933±130	1131±160	1131±161
glycated hemoglobin (%)	5.7±0.3	5.6±0.3	5.8±0.3	5.8±0.4
glycated hemoglobin (mmol mol <sup>-1</sup> )	38.4±3.6	37.8±3.6	40.1±3.5	39.4±4.1
triglycerides (mmol l <sup>-1</sup> )	1.26±0.96	1.24±0.72	1.64±0.95	1.63±0.98
cholesterol (mmol l <sup>-1</sup> )	5.34±0.86	5.22±0.87	5.46±1.09	5.43±1.02
LDL cholesterol (mmol l <sup>-1</sup> )	3.23±0.83	3.12±0.79	3.38±0.95	3.3±0.87
HDL cholesterol (mmol l <sup>-1</sup> )	1.47±0.4	1.56±0.71	1.37±0.36	1.39±0.41
Liver fat content (%)	2.85±2.74	2.86±3.1	10.72±8.76	10.18±7.57
Insulin sensitivity index (AU)	9.86±5.05	10.06±5.16	5.70±3.12	5.52±3.01
Insulin secretion (Disposition index) (AU)	1440±994	1627±1352	654±424	688±506
Hypertension no/yes (%)	56/39 (59/41)	63/33 (66/34)	155/185 (46/54)	152/181 (46/54)



Hyperlipidemia no/yes (%)	55/38 (59/41)	58/34 (63/37)	184/145 (56/44)	171/145 (54/46)
History of myocardial infarction no/yes (%)	91/3 (97/3)	97/1 (99/1)	325/7 (98/2)	314/10 (97/3)
History of stroke no/yes (%)	90/4 (96/4)	95/2 (98/2)	325/4 (99/1)	311/13 (96/4)
peripheral artery disease no/yes (%)	85/6 (93/7)	88/7 (93/7)	288/41 (88/12)	284/39 (88/12)
medication: angiotensine convertase inhibitors no/yes (%)	89/12 (88/12)	91/9 (91/9)	290/61 (83/17)	303/53 (85/15)
medication: angiotensine receptor blockers no/yes (%)	84/17 (83/17)	84/16 (84/16)	276/75 (79/21)	260/96 (73/27)
medication: thiazide diuretics no/yes (%)	93/8 (92/8)	92/8 (92/8)	306/45 (87/13)	301/55 (85/15)
medication: other diuretics no/yes (%)	98/3 (97/3)	98/2 (98/2)	335/16 (95/7)	341/15 (96/4)
medication: beta blockers no/yes (%)	88/13 (87/13)	86/14 (86/14)	272/79 (77/23)	273/83 (77/23)
medication: statins no/yes (%)	89/12 (88/12)	86/14 (86/14)	287/64 (82/18)	294/62 (83/17)
current smoking no/yes (%)	93/3 (97/3)	91/7 (93/7)	324/22 (94/6)	321/22 (94/6)
alcohol consumption n (%)				
1 none	20 (21)	11 (11)	29 (8)	42 (12)
2 rarely	30 (31)	43 (44)	157 (45)	147 (43)
3 week-ends	9 (9)	5 (5)	33 (10)	24 (7)
4 weekely 2-3	33 (34)	27 (27)	82 (24)	87 (26)
5 daily	5 (5)	13 (13)	44 (13)	40 (12)
highest education n (%)				
1 none	1 (1)	4 (4)	8 (2)	11 (3)
2 post secondary	46 (47)	53 (54)	160 (48)	154 (45)
3 bachelor or equivalent	18 (18)	15 (15)	85 (25)	89 (26)
4 master or equivalent	34 (34)	26 (27)	84 (25)	88 (26)

**Appendix Table 5**

Comparison of baseline variables (mean±SD) non-completers versus completers.

	Non-completer (n=197)	Completer (n=908)	p-value
Riskgroup n (%)			1
1 low risk	44 (22)	201 (22)	
2 high risk	153 (78)	707 (78)	
Intervention group n (%)			0.91
control	22 (11)	101 (11)	
conventional	101 (51)	451 (50)	
intensive	74 (38)	356 (39)	
sex female/male (%)	132/65 (67/33)	519/389 (57/43)	0.014
age (years)	54±12	59±10	<0.0001
weight (kg)	93.1±21.1	89.6±19.4	0.036
body mass index (kg m <sup>-2</sup> )	32.2±6.5	30.9±5.9	0.0091
waist circumference (cm)	104±16	102±14	0.19
waist-to-hip ratio	0.92±0.09	0.93±0.09	0.19
systolic blood pressure (mmHg)	136±16	139±17	0.048
diastolic blood pressure (mmHg)	86±10	86±11	0.98
fasting glucose (mmol l <sup>-1</sup> )	6.0±0.6	5.9±0.5	0.089
post-challenge glucose (mmol l <sup>-1</sup> )	7.5±1.9	7.6±1.7	0.7
glucose AUC (mmol min l <sup>-1</sup> )	1084±191	1088±173	0.79
glycated hemoglobin (mmol mol <sup>-1</sup> )	39.3±4.4	39.4±3.8	0.72
glycated hemoglobin (%)	5.7±0.4	5.8±0.3	0.72
triglycerides (mmol l <sup>-1</sup> )	1.53±0.86	1.55±0.95	0.83
cholesterol (mmol l <sup>-1</sup> )	5.33±0.98	5.41±1.01	0.31
LDL cholesterol (mmol l <sup>-1</sup> )	3.26±0.88	3.3±0.89	0.52
HDL cholesterol (mmol l <sup>-1</sup> )	1.39±0.38	1.41±0.44	0.59
Hepatic triglyceride content (%)	9.12±8.21	8.75±8	0.62
Insulin sensitivity index	6.38±3.68	6.58±4.04	0.52
Insulin secretion (Disposition index) (AU)	882.±660	863±781	0.73
Hypertension no/yes (%)	95/84 (53/47)	426/438 (49/51)	0.4
hyperlipidemia no/yes (%)	108/64 (63/37)	468/362 (56/44)	0.14
myocardial infarction no/yes (%)	172/4 (98/2)	827/21 (98/2)	1
stroke no/yes (%)	176/2 (99/1)	821/23 (97/3)	0.32
peripheral artery disease no/yes (%)	154/21 (88/12)	745/93 (89/11)	0.83
medication: angiotensine convertase inhibitors no/yes (%)	171/26 (87/13)	773/135 (85/15)	0.62
medication: angiotensine receptor blockers no/yes (%)	160/37(81/19)	704/204 (78/22)	0.3
medication: thiazide diuretics no/yes (%)	176/21 (89/11)	792/116 (87/13)	0.49
medication: other diuretics no/yes (%)	194/3 (98/2)	872/36 (96/4)	0.14
medication: beta blockers no/yes (%)	156/41 (79/21)	719/189 (79/21)	1

medication: statins no/yes (%)	173/24 888/12)	756/152 (83/17)	0.14
current smoking no/yes (%)	154/26 (86/14)	829/54 (94/6)	0.00021
alcohol use			0.025
1 none	31 (17)	102 (12)	
2 rarely	89 (50)	377 (42)	
3 week-ends	13 (7)	71 (8)	
4 weekly 2-3	31 (17)	229 (26)	
5 daily	16 (9)	102 (12)	
highest education			0.62
1 none	6 (3)	24 (3)	
2 post secondary	95 (52)	413 (47)	
3 bachelor or equivalent	38 (21)	207 (24)	
4 master or equivalent	44 (24)	232 (26)	

**Appendix Table 6**

Effect of conventional LI in low risk individuals versus high risk individuals.

\*ANCOVA, adjusted for baseline and center.

	<b>Between-group difference of conventional intervention *</b> (for HR-CONV, reference: LR-CONV beta coefficient ( $\pm$ SE))	<b>p-value</b>
age (years)	-0 ( $\pm$ 0)	0.6
weight (kg)	0.4 ( $\pm$ 0.6)	0.5
body mass index (kg m <sup>-2</sup> )	0.1 ( $\pm$ 0.2)	0.5
waist circumference (cm)	-1 ( $\pm$ 1)	0.6
waist-to-hip ratio	-0.02 ( $\pm$ 0.01)	0.008
lean mass percent	-5.5 ( $\pm$ 2.3)	0.02
fat mass percent	0.9 ( $\pm$ 0.5)	0.07
habitual physical activity score	0.1 ( $\pm$ 0.1)	0.5
systolic blood pressure (mmHg)	-3 ( $\pm$ 2)	0.09
diastolic blood pressure (mmHg)	-1 ( $\pm$ 1)	0.3
heart rate (1/min)	-0 ( $\pm$ 1)	0.7
fasting glucose (mmol l <sup>-1</sup> )	-0.16 ( $\pm$ 0.06)	0.006
post-challenge glucose (mmol l <sup>-1</sup> )	-0.55 ( $\pm$ 0.20)	0.008
glucose AUC (mmol min l <sup>-1</sup> )	-33 ( $\pm$ 20)	0.1
glycated hemoglobin (mmol mol <sup>-1</sup> )	-0.0 ( $\pm$ 0.4)	1
glycated hemoglobin (%)	-0.0 ( $\pm$ 0.0)	1
triglycerides (mmol l <sup>-1</sup> )	0.11 ( $\pm$ 0.07)	0.1
cholesterol (mmol l <sup>-1</sup> )	0.12 ( $\pm$ 0.08)	0.1
LDL cholesterol (mmol l <sup>-1</sup> )	0.09 ( $\pm$ 0.07)	0.2
HDL cholesterol (mmol l <sup>-1</sup> )	0.04 ( $\pm$ 0.03)	0.2
C-reactive protein (mg dl <sup>-1</sup> )	0.1 ( $\pm$ 0.8)	0.9
Aspartate aminotransferase (Units l <sup>-1</sup> )	0.1 ( $\pm$ 1.4)	0.9
Alanin aminotransferase (Units l <sup>-1</sup> )	0.3 ( $\pm$ 1.5)	0.8
Gamma glutamyltransferase (Units l <sup>-1</sup> )	2.4 ( $\pm$ 2.1)	0.3
Insulin sensitivity index	-0.1 ( $\pm$ 0.5)	0.9
Insulin secretion (Disposition index) (AU)	226 ( $\pm$ 134)	0.09
Liver fat content (%)	0.1 ( $\pm$ 0.6)	0.9
Framingham 10-year-CV-risk (%)	-0.4 ( $\pm$ 1.0)	0.7

## Calculations

$$\text{Insulin sensitivity index (Matsuda - ISI)} = \frac{10000}{\sqrt{(G_0 * I_0) * (G_{mean} * I_{mean})}}$$

$$\text{Insulinogenic Index: IGI} = \frac{\Delta I_{0,30}}{\Delta G_{0,30}}$$

$$\text{Disposition Index: (Insulin sensitivity index) * (Insulinogenic index)}$$

$G_{mean}$  = mean plasma glucose 0,30,60,90,120 min during OGTT

$I_{mean}$  = mean plasma glucose 0,30,60,90,120 min during OGTT

$G_0$  = fasting plasma glucose,  $I_0$  = fasting plasma insulin

## Participating Investigators

University Hospital Tübingen:

Andreas Fritsche, Robert Wagner, Martin Heni, Kostantinos Kantartzis, Jürgen Machann, Fritz Schick, Rainer Lehmann, Andreas Peter, Corinna Dannecker, Louise Fritsche, Vera Valenta, Norbert Stefan, Hans-Ulrich Häring

DZD Head Office:

Renate Schick

University Hospital Heidelberg:

Peter Paul Nawroth, Stefan Kopf

German Institute of Human Nutrition:

Andreas FH Pfeiffer, Stefan Kabisch, Ulrike Dambeck, Annette Schürmann

University of Leipzig:

Michael Stumvoll, Matthias Blüher

Technical University Dresden:

Andreas L Birkenfeld, Peter Schwarz, Stefan Bornstein

Technical University Munich:

Hans Hauner, Julia Clavel

Ludwig-Maximilians University Munich:  
Jochen Seißler, Andreas Lechner

Heinrich-Heine University Düsseldorf:  
Karsten Müssig, Katharina Weber, Michael Roden

Helmholtz Center Munich:  
Michael Laxy, Martin Hrabe de Angelis

### **Data and Resource Availability**

Due to ethical regulations, we cannot share individual participant data. Mean values and confidence intervals of all analysed patient-level data are available and maybe shared upon reasonable request. Study protocol, statistical analysis plan and analytic code used to generate results are available upon reasonable request.

### **Financial information**

Funding: The DZD is funded by the German Federal Ministry for Education and Research (01GI0925).